Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
“Independently published in vitro studies demonstrate that pan-PI3K inhibition has some desirable effects on chemotaxis and proliferation inhibition in CLL B-cells over delta isoform-selective PI3K inhibition, which provides a rationale to clinically explore the therapeutic activity of pan-PI3K inhibition with SF1126”
Late-Breaking Abstract No. LB-291 - "Translational studies of the dual mTOR-PI3K inhibitor SF1126"
Results of in vitro studies presented at AACR demonstrate broad anti-tumor activity with SF1126 across six lymphoma cell lines and support expanded Phase I clinical evaluation in patients with certain B-cell malignancies, such as such as indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). Results of in vivo studies presented at AACR support combination trials with SF1126 and bortezomib in multiple myeloma. A copy of the abstract can be accessed through the AACR website, www.aacr.org.
"Independently published in vitro studies demonstrate that pan-PI3K inhibition has some desirable effects on chemotaxis and proliferation inhibition in CLL B-cells over delta isoform-selective PI3K inhibition, which provides a rationale to clinically explore the therapeutic activity of pan-PI3K inhibition with SF1126," said Joseph Garlich, Ph.D., Semafore's Chief Scientific Officer. "Accordingly, we are exploring the therapeutic activity of SF1126 in CLL and other B-cell malignancies. The encouraging data presented at AACR provided additional support for the expansion of our Phase I clinical study into this disease setting and the first such patient was dosed earlier this month."
Semafore Pharmaceuticals also announced today that the company has entered into an agreement with Technomark Life Sciences for the Phase I expansion of SF1126 in B-cell malignancies and ongoing clinical activities. Technomark's established product development and regulatory capabilities will help accelerate further clinical research with SF1126.
SOURCE Semafore Pharmaceuticals
Researchers identify increased brain tumor risk with specific contraceptive use